Chemo-Free HER2+ Breast Cancer Treatment Achieves Excellent 5-Year Survival
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
Summary
The WSG TP-II trial compared two neoadjuvant strategies for hormone receptor-positive, HER2-positive early breast cancer: endocrine therapy combined with trastuzumab and pertuzumab versus paclitaxel chemotherapy combined with the same HER2-targeting drugs. Although paclitaxel produced higher rates of pathologic complete response (56% vs 24%), the 5-year survival outcomes were remarkably similar and excellent across both arms. Patients in the endocrine therapy arm achieved 100% overall survival at 5 years, compared to 97.9% in the chemotherapy arm. Invasive disease-free survival also favored the endocrine therapy group. These findings suggest that a meaningful subset of HER2-positive breast cancer patients may safely forgo traditional chemotherapy, potentially sparing them significant toxicity, while still achieving outstanding long-term outcomes through a more targeted, de-escalated approach.
Detailed Summary
Breast cancer treatment is increasingly moving toward precision medicine, and a key question is whether some patients can safely avoid the toxicity of chemotherapy. The WSG TP-II trial directly addresses this question in hormone receptor-positive, HER2-positive early breast cancer — a subtype that responds to both hormonal and HER2-targeted therapies.
This multicenter, randomized phase II trial enrolled 207 patients and compared 12 weeks of neoadjuvant trastuzumab plus pertuzumab combined with either endocrine therapy or weekly paclitaxel chemotherapy. The primary endpoint — pathologic complete response (pCR), meaning no residual cancer at surgery — strongly favored chemotherapy (56.4% vs 23.7%). Despite this, both arms moved forward to adjuvant dual HER2 blockade, with additional chemotherapy mandatory only for patients without pCR.
The 5-year survival results are striking. Patients in the endocrine therapy arm achieved 100% overall survival, compared to 97.9% in the chemotherapy arm. Invasive disease-free survival rates were 97.7% versus 79.8%, respectively — a surprising advantage for the less aggressive upfront treatment. Event-free survival rates were comparable between arms at approximately 92% and 95%.
These results suggest that lower pCR rates in the endocrine therapy arm did not translate into worse long-term survival, at least over a 5-year horizon. This likely reflects the biology of hormone receptor-positive/HER2-positive tumors, which may be effectively controlled by subsequent targeted therapies even when pCR is not initially achieved.
For oncologists and patients, these findings open the door to meaningful de-escalation of upfront chemotherapy in selected patients. However, several caveats apply. The trial is phase II with a relatively small sample size, limiting statistical power. The 5-year window may be insufficient to detect late recurrences, particularly in hormone receptor-positive disease known for late relapses. Full data access beyond the abstract is needed to assess subgroup effects.
Key Findings
- Endocrine therapy plus dual HER2 blockade achieved 100% 5-year overall survival in HR+/HER2+ early breast cancer.
- Paclitaxel produced far higher pathologic complete response rates (56% vs 24%) but did not improve 5-year overall survival.
- Invasive disease-free survival at 5 years was 97.7% for endocrine therapy arm versus 79.8% for chemotherapy arm.
- De-escalated, chemo-free neoadjuvant strategy with pCR-guided adjuvant therapy appears safe and effective.
- Findings support considering chemotherapy omission in selected hormone receptor-positive/HER2-positive patients.
Methodology
This was a multicenter, randomized, open-label phase II trial (NCT03272477) enrolling 207 patients with HR+/HER2+ early breast cancer, randomized 1:1 to endocrine therapy or paclitaxel, each combined with trastuzumab and pertuzumab for 12 weeks. All patients received adjuvant dual HER2 blockade; non-pCR patients received additional chemotherapy. Final 5-year survival analysis is reported here.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; key subgroup data, statistical analyses, and safety profiles are unavailable. The phase II design and modest sample size of 207 patients limit the statistical power to detect meaningful differences in survival endpoints. A 5-year follow-up may be insufficient for HR-positive breast cancer, which is known for late relapses beyond 5 years.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.